4169.Tw
4169.TW is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the biotechnology segment.
Business. 4169.TW is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the biotechnology segment.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4169.TW is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the biotechnology segment.
The company maintains a strong liquidity position, with a current ratio of 7.47, indicating a high ability to meet short-term obligations. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. The debt-to-equity ratio is low at 0.04, suggesting a conservative capital structure with minimal reliance on debt financing.
Profitability metrics show a return on equity of 1.82% and a return on assets of 1.59%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The operating margin is 2.72% (calculated from operating income of 18,654,000 TWD and revenue of 685,491,000 TWD), which is relatively low compared to industry benchmarks. The net profit margin is 0.28% (19,170,000 TWD / 685,491,000 TWD), indicating that the company is generating limited net returns on its revenue.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the biotechnology and pharmaceutical sectors.
The company's growth trajectory is modest, with no disclosed revenue growth rates or future projections. The operating cash flow of 37,131,000 TWD and free cash flow of 19,201,000 TWD suggest the company is generating positive cash from operations, but the capital expenditure of -2,829,000 TWD indicates minimal investment in new projects or expansion.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has a low probability of issuing new shares in the near term, and no significant dilution sources are identified in the available documentation. The risk of dilution is further supported by the fact that the number of basic and diluted shares outstanding is the same.
Recent events and filings do not indicate any material changes in the company's operations or financial position. Analysts have provided a strong buy recommendation, with a mean price target of 194.00 TWD, suggesting a positive outlook despite the company's current financial performance.
- The company has a strong liquidity position with a current ratio of 7.47, but a negative net cash position after subtracting total debt introduces some liquidity risk.
- Profitability metrics are below industry benchmarks, with a return on equity of 1.82% and a return on assets of 1.59%.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, increasing exposure to market-specific risks.
- The company is generating positive operating and free cash flows, but capital expenditures are minimal, indicating limited investment in new projects or expansion.
- Analysts have provided a strong buy recommendation with a mean price target of 194.00 TWD, suggesting a positive outlook despite the company's current financial performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4169.TW Market data — financials · 2026-05-26
- Tcm Biotech International Corp Market data — analyst estimates · 2026-05-26